Omnicell Adjusts 2014 Guidance To Include Surgichem Results - Quick Facts

(RTTNews) - Omnicell Inc. (OMCL) announced that it has completed the acquisition of Surgichem Limited, a subsidiary of Bupa Care Homes plc. Omnicell said its financial guidance for 2014 is adjusted to include the expected results of Surgichem following the acquisition.

Omnicell now expects its 2014 revenue to be between $420 million and $430 million; compared to prior guidance of between $415 million and $425 million. The company now expects its non-GAAP earnings per share to be $1.18 to $1.24, compared to previous guidance of between $1.17 and $1.23 .

Analysts polled by Thomson Reuters expect the company to report 2014 profit per share of $1.23 on revenue of $424.57 million. Analysts' estimates typically exclude special items.

Omnicell said it expects initial costs to integrate Surgichem to be incurred during the first 12 months following the acquisition, and following that period, the acquisition will be accretive by approximately $0.03 per share annually.

Surgichem will be integrated with Omnicell's existing UK business, MTS Medication Technologies Limited in the coming months.